No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INCY Incyte
- 50.640
- -1.100-2.13%
Trading Apr 25 11:15 ET
11.37BMarket Cap19.11P/E (TTM)
51.850High50.360Low503.11KVolume51.580Open51.740Pre Close25.56MTurnover0.27%Turnover Ratio19.11P/E (Static)224.53MShares75.74052wk High2.19P/B9.47BFloat Cap50.27052wk Low--Dividend TTM186.98MShs Float153.150Historical High--Div YieldTTM2.88%Amplitude1.850Historical Low50.796Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84
Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $92 to $84.
Truist Financial Keeps Their Buy Rating on Incyte (INCY)
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
